Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.01SPGP 1.22ZUQ.TO 1.43NVDA 7GL 2.22MRK -4.11IEMG 1.85GEV 39.24
Patheon (PTI.TO)
The ultimate 360° Tracker Your financial life in one place, automatically

Patheon (PTI.TO)

0.00
-0.00 (0.00%)
6 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
HOLD

Patheon(PTI.TO)

Feb 17, 2004
Has been a big disappointment. Have run into difficulties with their British facilities. Strong management team. May be in a consolidation phase. Maybe in the penalty box for a quarter or two.
Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$10.85

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Feb 10, 2004
There is hope that they will turn around sales. In the penalty box for 1-2 more quarters.
Photo of Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$11.00

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Feb 09, 2004
Does everything it does very well. Disappointment in sales in Canada. Profitable company. Selling at almost 3x book value. COuld reach $15
Photo of Michael SprungMichael SprungUnlock Rating
$11.00

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Jan 28, 2004
Delivered lousy quarter. Buy
Photo of Andrew McCreathAndrew McCreathUnlock Rating
$11.29

Stock price when the opinion was issued

biotechnologypharmaceutical
WATCH

Patheon(PTI.TO)

Jan 27, 2004
Disappointment in the earnings and dead money until you see another quarter.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$11.06

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Jan 27, 2004
Has come down with a lot of the biotech stocks. Have real earnings. One of the Premier manufacturer of drugs. Expect they will earn $.50¢ next year and $.60¢ a year after.
Photo of Michael SprungMichael Sprung
Owned
Unlock Rating
$11.06

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Jan 26, 2004
They delivered another lousy quarter. Could be in trouble if Aventis loses in the hostile takeover bid by Sanofi and they close its plants.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$11.25

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Patheon(PTI.TO)

Jan 22, 2004
Dropped because of a disappointing quarter. A screaming buy. Very solid management team.
Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$11.19

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Jan 22, 2004
In a stock market that has been rocketing for a year, this is a stock that has gone lower. It will get hurt the most in any pull back.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$11.19

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Jan 21, 2004
Any kind of bad news, such as energy prices, will drop the price very quickly because of the amount of US investment. Nervous about this.
Photo of Garth JestleyGarth Jestley
No
Unlock Rating
$17.70

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Jan 07, 2004
Was a big disappointment. Made money, but not as much as had been expected. A very solid growth story. Will be doing moredrug trials which is very lucrative. Cheap.
Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$11.19

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Patheon(PTI.TO)

Jan 05, 2004
A good basic business, but probably thin margins. Not the best area to be in. The low price may make it worth while, but don't expect too much.
Photo of Michael SmedleyMichael Smedley
No
Unlock Rating
$11.61

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Dec 18, 2003
Has been a disappointment. A difficult business.
Photo of Michael SmedleyMichael Smedley
No
Unlock Rating
$10.74

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Patheon(PTI.TO)

Dec 16, 2003
Pharmaceuticals in general have been weak all year long. There is no earnings potential.
Photo of David BurrowsDavid BurrowsUnlock Rating
$13.12

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Patheon(PTI.TO)

Dec 15, 2003
Trying to perform a little bit of a support base. Expects a little bit of upside over the next 3/6 months. If it drops below the lows in March and November, it could be trouble. Put a stop loss at those points.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTAUnlock Rating
$13.28

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 91 to 105 of 194 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.695$36.555
ET -0.165$18.905
MAIR 0$
RKLB 6.825$109.215
SESG-O 0$

Today's Top Picks

HMP.TO 0.01$9.76
SPGP 1.22$121.61
ZUQ.TO 1.43$108.9
NVDA 7$212.19
GL 2.22$168.98

Popular Articles

Latest Sell Signals

PRGO -0.255$10.735
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica